Pasireotide vs Tirzepatide
Overview
Pasireotide is primarily a hormonal peptide, while Tirzepatide is used for weight management & metabolic.
This page compares Pasireotide and Tirzepatide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Tirzepatide | |
|---|---|---|
| Category | Hormonal | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 2.5-15 mg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | weekly |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Enhanced weight loss, improved insulin sensitivity, better glycemic control, cardiovascular benefits |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Similar to semaglutide: GI disturbances, nausea, potential pancreatitis |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Tirzepatide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Pasireotide: FDA-approved. Tirzepatide: FDA-approved.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Tirzepatide is typically dosed at 2.5-15 mg (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Tirzepatide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Tirzepatide?
- Pasireotide is primarily a hormonal peptide, while Tirzepatide is used for weight management & metabolic. Pasireotide is FDA-approved for one or more indications, whereas Tirzepatide is FDA-approved for one or more indications.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Tirzepatide used for?
- Dual GIP/GLP-1 agonist for weight loss.
- Can you take Pasireotide and Tirzepatide together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Tirzepatide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Tirzepatide FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Tirzepatide is FDA-approved for one or more indications.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Tirzepatide — full monograph: mechanism, research, dosing & references